Person:
Min, Changwook

Profile Picture

Email Address

AA Acceptance Date

Birth Date

Research Projects

Organizational Units

Job Title

Last Name

Min

First Name

Changwook

Name

Min, Changwook
Author's Publications: search.filters.isAuthorOfPublication.179eccf4-ea35-4199-bfab-8b72c929c5f0

Search Results

Now showing 1 - 2 of 2
  • Thumbnail Image
    Publication
    Chip-based analysis of exosomal mRNA mediating drug resistance in glioblastoma
    (Nature Pub. Group, 2015) Shao, Huilin; Chung, Jaehoon; Lee, Kyungheon; Balaj, Leonora; Min, Changwook; Carter, Bob S.; Hochberg, Fred H.; Breakefield, Xandra; Lee, Hakho; Weissleder, Ralph
    Real-time monitoring of drug efficacy in glioblastoma multiforme (GBM) is a major clinical problem as serial re-biopsy of primary tumours is often not a clinical option. MGMT (O6-methylguanine DNA methyltransferase) and APNG (alkylpurine-DNA-N-glycosylase) are key enzymes capable of repairing temozolomide-induced DNA damages and their levels in tissue are inversely related to treatment efficacy. Yet, serial clinical analysis remains difficult, and, when done, primarily relies on promoter methylation studies of tumour biopsy material at the time of initial surgery. Here we present a microfluidic chip to analyse mRNA levels of MGMT and APNG in enriched tumour exosomes obtained from blood. We show that exosomal mRNA levels of these enzymes correlate well with levels found in parental cells and that levels change considerably during treatment of seven patients. We propose that if validated on a larger cohort of patients, the method may be used to predict drug response in GBM patients.
  • Thumbnail Image
    Publication
    Magnetic Nanoparticles and MicroNMR for Diagnostic Applications
    (Ivyspring International Publisher, 2012) Shao, Huilin; Min, Changwook; Issadore, David; Liong, Monty; Yoon, Tae-Jong; Weissleder, Ralph; Lee, Hakho
    Sensitive and quantitative measurements of clinically relevant protein biomarkers, pathogens and cells in biological samples would be invaluable for disease diagnosis, monitoring of malignancy, and for evaluating therapy efficacy. Biosensing strategies using magnetic nanoparticles (MNPs) have recently received considerable attention, since they offer unique advantages over traditional detection methods. Specifically, because biological samples have negligible magnetic background, MNPs can be used to obtain highly sensitive measurements in minimally processed samples. This review focuses on the use of MNPs for in vitro detection of cellular biomarkers based on nuclear magnetic resonance (NMR) effects. This detection platform, termed diagnostic magnetic resonance (DMR), exploits MNPs as proximity sensors to modulate the spin-spin relaxation time of water molecules surrounding the molecularly-targeted nanoparticles. With new developments such as more effective MNP biosensors, advanced conjugational strategies, and highly sensitive miniaturized NMR systems, the DMR detection capabilities have been considerably improved. These developments have also enabled parallel and rapid measurements from small sample volumes and on a wide range of targets, including whole cells, proteins, DNA/mRNA, metabolites, drugs, viruses and bacteria. The DMR platform thus makes a robust and easy-to-use sensor system with broad applications in biomedicine, as well as clinical utility in point-of-care settings.